Objective Several indices have been proposed to assess disease activity in patients with Systemic Lupus Erythematosus (SLE). Recent studies have showed a prevalence of flare between 28–35.3%, persistently active disease (PAD) between 46%–52% and serologically active clinically quiescent (SACQ) disease ranging from 6 to 15%. Our goal was to evaluate the flare, PAD and SACQ rate incidence in a cohort of SLE patients over a 2-year follow-up. Methods We evaluated 394 SLE patients. Flare was defined as an increase in SLEDAI-2K score of ≥4 from the previous visit; PAD was defined as a SLEDAI-2K score of ≥4, on >2 consecutive visits; SACQ was defined as at least a 2-year period without clinical activity and with persistent serologic activity. Results Among the 95 patients eligible for the analysis in 2009, 7 (7.3%) had ≥1 flare episode, whereas 9 (9.4%) had PAD. Similarly, among the 118 patients selected for the analysis in 2010, 6 (5%) had ≥1 flare episode, whereas 16 (13.5%) had PAD. Only 1/45 patient (2.2%) showed SACQ during the follow-up. Conclusion We showed a low incidence of flare, PAD and SACQ in Italian SLE patients compared with previous studies which could be partly explained by ethnic differences.
References
[1]
Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, et al. (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69: 1269–74.
[2]
Griffiths B, Mosca M, Gordon C (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19: 685–708.
[3]
Gladman DD, Urowitz MB, Kagal A, Hallett D (2000) Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 27: 377–9.
[4]
Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353: 2550–8.
[5]
Nikpour M, Urowitz MB, Iba？ez D, Gladman DD (2009) Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 61: 1152–8.
[6]
Conti F, Ceccarelli F, Perricone C, Massaro L, Spinelli FR, et al. (2010) Low incidence of flare and persistent active disease in a cohort of Italian patients with systemic lupus erythematosus: comment on the article by Nikpour, et al. Arthritis Care Res (Hoboken) 62: 899–900.
[7]
Steiman AJ, Gladman DD, Iba？ez D, Urowitz MB (2010) Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 37: 1822–7.
[8]
Gladman DD, Urowitz MB, Keystone EC (1979) Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 66: 210–5.
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, et al. (2000) The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 9: 445–50.
[13]
Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, et al. (1997) The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 40: 809–13.
[14]
Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y (2012) Systemic lupus erythematosus one disease or many? Autoimmun Rev 11: 593–5.
[15]
Sciascia S, Ceberio L, Garcia-Fernandez C, Rocatello D, Karim Y, et al.. (2012) Systemic lupus erythematosus and infections: Clinical importance of conventional and upcoming biomarkers. Autoimmune Rev: Apr. 1.
[16]
Romero-Diaz J, Isenberg D, Ramsey-Goldman R (2011) Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res 63 Suppl 11S37–46.
[17]
Luijten KM, Tekstra J, Bijlsma JW, Bijl M (2012) The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment.Autoimmun Rev. 11: 326–9.
[18]
Conti F, Alessandri C, Perricone C, Scrivo R, Rezai S, et al. (2012) Neurocognitive dysfunction in systemic lupus erythematosus: association with antiphospholipid antibodies, disease activity and chronic damage. PLoS One 7: e33824.
